# Research Progress of Anti-lung Cancer Drug-related Interstitial Lung Disease

## TL;DR

This paper reviews drug-induced interstitial lung disease (ILD) caused by anti-lung cancer drugs, focusing on diagnosis and treatment to improve patient outcomes.

## Contribution

The paper provides a comprehensive review of the clinical management and research progress of anti-lung cancer drug-related ILD.

## Key findings

- Anti-lung cancer drugs can cause ILD with significant mortality.
- Multidisciplinary treatment is essential for managing drug-induced ILD.
- Early detection and proper diagnosis improve patient prognosis.

## Abstract

全球范围内肺癌的发病率和病死率均为最高。随着医学研究的进展及治疗手段的丰富，患者的生存期得以改善，但仍需关注用药的相关不良反应，其中药物性间质性肺病（drug-induced interstitial lung disease, DI-ILD）最为常见，抗肺癌药物相关ILD是指经过抗肺癌治疗出现肺间质炎症和纤维化的病变，而不良预后以及较高的病死率与此有关；并且抗肺癌药物相关ILD的临床管理也需要多学科协作（multi-disciplinary treatment, MDT）模式应对其复杂的诊断和治疗。本文综述了抗肺癌药物相关ILD在流行病学、分子生物学、基因组学和遗传学、诊断以及治疗等方面的研究，为临床医生提供参考，旨在尽早发现抗肺癌药物相关ILD，改善患者预后和生活质量。

Incidence of interstitial lung disease induced by different categories of anti-lung cancer drugs

Common imaging and pathological manifestations of ILD associated with anti-lung cancer drugs

Auxiliary information of other diagnostic tests